RAB5C, member RAS oncogene family pseudogene 2Genealiases: []
Q-omics provides the consensus-scored RAB5CP2 profile across patient tissues and cancer cell-line models. RAB5CP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAB5CP2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RAB5CP2 RNA expression shows 10,419 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, LUSC, and DLBC as cancer lineages where RAB5CP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB5CP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB5CP2 survival associations across molecular data types. RAB5CP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB5CP2 RNA expression–survival associations across cancer types. High RAB5CP2 expression shows unfavorable associations in ACC and KIRC, but favorable associations in KIRP, HNSC, STAD and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAB5CP2 RNA expression.
This table summarizes RAB5CP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB5CP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB5CP2 shows lower tumor expression in LUSC and THCA and higher tumor expression in COAD, LIHC and BRCA. The LUSC box plot shows higher RAB5CP2 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p < 0.001).
This table shows molecular features associated with RAB5CP2 in patient tissues and cancer cell lines. In patient samples, RAB5CP2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
